Definium Therapeutics, Inc.

Definium Therapeutics Highlights DT120 ODT (Lysergide Tartrate) Clinical Advancements and Commercial Strategy at Investor and Analyst Day

Definium Therapeutics to Participate at Upcoming Investor Conferences and Events

Definium Therapeutics Announces New Employee Inducement Grants

Definium Therapeutics to Host Investor and Analyst Day in New York on April 22, 2026

Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates